VC dollars driving nanotech drug development for cancer

09/12/2007 | Wall Street Journal (free content), The

Investors increasingly are funding nanotechnology-based anti-cancer drugs under development by companies including BIND Biosciences, Tempo Pharmaceuticals and Avidimer Therapeutics. Venture capital firms are also looking at promising applications of nanotechnology in RNA-interference chemistries, such as those being developed by Interdigm Corp., and improved diagnosis, including work by Kereos.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA